J7629 HCPCS Level II code: Bitolterol mesylate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
J7629 is the HCPCS code for “Bitolterol mesylate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J7629Bitolterol mesylate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
Short description: Bitolterol mesylate comp unt
HCPCS · United States
Notes for J7629
As CMS prints them, with any note J7629 takes from the headings above it.
Note
- CMS processing note 0135: MEDICARE BENEFIT POLICY MANUAL, PUB 100.2, CHAPTER 15, SECTION 110.3 (100.02,15,110.3).
Medicare details
The indicators CMS publishes with J7629 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Drugs Administered through DME
- Added
- Jan 1, 2000
Where J7629 sits
- 1J codesDrugs administered other than orally
- 2Active code J7629Bitolterol mesylate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J7629 mean?
J7629 is the HCPCS code for “Bitolterol mesylate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J7629?
CMS lists J7629’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J7629
All J codesJ7620Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dmeJ7622Beclomethasone, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7624Betamethasone, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7626Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mgJ7627Budesonide, inhalation solution, compounded product, administered through dme, unit dose form, up to 0.5 mgJ7628Bitolterol mesylate, inhalation solution, compounded product, administered through dme, concentrated form, per milligramJ7631Cromolyn sodium, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 10 milligramsJ7632Cromolyn sodium, inhalation solution, compounded product, administered through dme, unit dose form, per 10 milligramsJ7633Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per 0.25 milligramJ7634Budesonide, inhalation solution, compounded product, administered through dme, concentrated form, per 0.25 milligramJ7635Atropine, inhalation solution, compounded product, administered through dme, concentrated form, per milligramJ7636Atropine, inhalation solution, compounded product, administered through dme, unit dose form, per milligram